Enzymothérapie substitutive chez neuf patients atteints de la maladie de Fabry

Éric Alamartine

doi:10.1051/medsci/20052111s62

Accueil

Tous les numéros

Volume 21 (Décembre 2005) Numéro spécial

Med Sci (Paris), 21 (2005) 62-65

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 21, Décembre 2005 Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches


Page(s)		62 - 65
Section		M/S revues
DOI		https://doi.org/10.1051/medsci/20052111s62
Publié en ligne		15 novembre 2005

Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha galactosidase A replacement therapy in Fabry’s disease.N Engl J Med 2001; 345 : 9–16. [Google Scholar]
Warnock DG. Fabry disease : diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2004; 14 : 87–95. [Google Scholar]
Ries M, Bove Bettis KE, Choyke P, et al. Parapelvic kidney cysts : a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004; 66 : 978–82. [Google Scholar]
Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease : a pilot study. Kidney Int 2004; 65 : 1381–5. [Google Scholar]
Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 2000; 69 : 2337–9. [Google Scholar]
De Schoemakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry’s disease : beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18 : 33–5. [Google Scholar]
Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75 : 65–74. [Google Scholar]
Young E, Milks K, Morris P, et al. Is globotriaosylceramide a useful marker in Fabry disease ? Acta Paediatr 2005; 94 (suppl) : 51–4. [Google Scholar]
Siamopoulos KC. Fabry disease : kidney involvement and enzyme replacement therapy. Kidney Int 2004; 65 : 744–53. [Google Scholar]
Lindthorst GL, Hollak CEM, Donker-Koopman E, et al. Enzyme therapy for Fabry disease : neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004; 66 : 1589–95. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha galactosidase A replacement therapy in Fabry’s disease.N Engl J Med 2001; 345 : 9–16. [Google Scholar]

[2] Warnock DG. Fabry disease : diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2004; 14 : 87–95. [Google Scholar]

[3] Ries M, Bove Bettis KE, Choyke P, et al. Parapelvic kidney cysts : a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004; 66 : 978–82. [Google Scholar]

[4] Mignani R, Panichi V, Giudicissi A, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease : a pilot study. Kidney Int 2004; 65 : 1381–5. [Google Scholar]

[5] Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 2000; 69 : 2337–9. [Google Scholar]

[6] De Schoemakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry’s disease : beneficial clinical effect on vital organ function. Nephrol Dial Transplant 2003; 18 : 33–5. [Google Scholar]

[7] Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75 : 65–74. [Google Scholar]

[8] Young E, Milks K, Morris P, et al. Is globotriaosylceramide a useful marker in Fabry disease ? Acta Paediatr 2005; 94 (suppl) : 51–4. [Google Scholar]

[9] Siamopoulos KC. Fabry disease : kidney involvement and enzyme replacement therapy. Kidney Int 2004; 65 : 744–53. [Google Scholar]

[10] Lindthorst GL, Hollak CEM, Donker-Koopman E, et al. Enzyme therapy for Fabry disease : neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004; 66 : 1589–95. [Google Scholar]